Peer Reviewed
Drug update

Vortioxetine: a new option for depression

John Wg Tiller
Abstract
Vortioxetine was approved by the TGA in 2014 for treatment of adults with major depressive disorder. It adds to the repertoire of antidepressants available for individualising treatment and may have particular benefits for patients with cognitive impairment associated with depression.
Key Points

    Vortioxetine is a new antidepressant that appears generally well tolerated; the most common side effect is nausea. It has been shown to be effective in relieving depression, anxiety and associated cognitive symptoms in depressed patients. It is suitable for use in adult patients with depression, including the elderly, in general practice as well as specialist psychiatric practice.

    Picture credit: © Rob Lewine/Tetra Images/Diomedia.com. Model used for illustrative purposes only.

Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?